Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer

The triple-negative breast cancer (TNBC) subtype comprises approximately 15% of all breast cancers and is associated with poor long-term outcomes. Classical chemotherapy remains the standard of treatment, with toxicity and resistance being major limitations. TNBC is a high metabolic group, and antim...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Elena López-Camacho, Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Irene Dapía, Rocío López-Vacas, Andrea Zapater-Moros, María Isabel Lumbreras-Herrera, Pedro Arias, Pilar Zamora, Juan Ángel Fresno Vara, Enrique Espinosa
Format: Artigo
Langue:Inglês
Publié: Elsevier 2022-05-01
Collection:Biomedicine & Pharmacotherapy
Sujets:
Triple-negative breast cancer
Antimetabolic drugs
Chemotherapy drugs
Synergism
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S0753332222002323
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires